Company Overview of Tocagen Inc.
Tocagen Inc., a biopharmaceutical company, discovers, develops, and commercializes products for the treatment of cancer. The company focuses on developing a treatment for High Grade Glioma, a type of brain cancer that includes glioblastoma multiforme and anaplastic astrocytomas. Its products include Toca 511 and Toca FC that allows selective targeting of cancer cells, as well as a selective, local, and systemic antitumor immune response without off-target toxicity; and Toca Gamma that leverages the immune system to clear locally injected cancerous tumors, as well as to create an arsenal of targeted immune cells to kill more distant metastatic cancer cells. The company was founded in 2007 and...
3030 Bunker Hill Street
San Diego, CA 92109
Founded in 2007
Key Executives for Tocagen Inc.
Co-Founder, Chief Executive Officer, President and Director
Co-Founder and Executive Vice President of Research & Pharmaceutical Development
Co-Founder, Executive Vice President of Corporate Development and Director
Chief Financial Officer, Executive Vice President and Director
Head of Business Development and Product Manager
Compensation as of Fiscal Year 2015.
Tocagen Inc. Key Developments
FDA Grants Orphan Drug Designation for Tocagen's Toca 511 & Toca FC
Aug 25 15
Tocagen Inc. announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company's immuno-oncology product candidate, Toca 511 & Toca FC, for the treatment of glioblastoma. As previously announced, the investigational drug was granted FDA Fast Track designation for the treatment of recurrent high-grade glioma, which includes glioblastoma and anaplastic astrocytoma, and is poised to move into a pivotal clinical trial later this 2015. Toca 511 & Toca FC is an investigational treatment that is designed to program cancer cells to convert the prodrug 5-FC into the anticancer drug 5-FU, killing tumor cells and leading to activation of the immune system through a combination of mechanisms. Toca 511 is a retroviral replicating vector (RRV) that selectively delivers a gene for the enzyme cytosine deaminase to the tumor. Patients then take oral cycles of Toca FC, a novel formulation of an antifungal drug, which is converted within infected cancer cells into the FDA-approved anticancer drug, 5-fluorouracil (5 FU). As a result, in addition to direct 5-FU mediated killing the immune system is activated to recognize and kill cancer cells, leaving healthy cells unharmed. Immune activation locally in the tumor occurs through a combination of mechanisms that together break the barrier of immune tolerance and may lead to durable tumor response.
FDA Grants Fast Track Designation to Tocagen's Toca 511 & Toca FC for Treatment of Recurrent High Grade Glioma
Jul 9 15
-? Tocagen Inc. , a clinical-stage immuno-oncology company, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead iTocagen Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead
immuno-oncology product, Toca 511 & Toca FC, for the treatment of recurrent high grade glioma, which includes
glioblastoma and anaplastic astrocytoma. This treatment will enter a registrational study called Toca 5 later
this year in patients with recurrent glioblastoma or anaplastic astrocytoma. Toca 511 & Toca FC is an immuno-oncology therapy that will advance into a registrational trial in 2015 in patients with recurrent glioblastoma or anaplastic astrocytoma. Toca 511 & Toca FC are designed to selectively transform cancer cells so they produce a chemotherapy drug within the tumor while also activating the immune system against the tumor with local and systemic benefits. Toca 511 is a retroviral replicating vector (RRV) that selectively delivers a gene for the enzyme cytosine deaminase to the cancer cells. The patient then takes
oral cycles of Toca FC, a novel formulation of an antifungal drug, which is converted into the FDA-approved
chemotherapy drug, 5-fluorouracil (5 FU). As a result, infected cancer cells are selectively killed,
subsequently activating the immune system to recognize cancer cells while leaving healthy cells unharmed.
Immune activation locally in the tumor occurs through a combination of mechanisms which leads to breaking of
immune tolerance and activation of the immune system selectively against the cancer cells.
Tocagen Inc. Appoints Asha Das as Vice President of Clinical Development and Medical Affairs
Jun 17 15
Tocagen Inc. announced Asha Das, M.D. has been named vice president of clinical development and medical affairs. Prior to joining she held positions of increasing responsibility at Genentech, including activities related to the approval and launch of Avastin in recurrent glioblastoma, expansion into platinum-resistant ovarian cancer and metastatic cervical cancer as well as clinical activities related to PD-L1.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|